Tirzepatide works on two clocks, and they run at very different speeds. Appetite shifts within the first weeks, while weight loss builds for most of a year and depends on how far up the dose ladder a person goes.
The steps themselves are laid out in tirzepatide dosage. This page follows the timeline the trials recorded.
How the label starts it
The Zepbound label starts at 2.5 mg once weekly for 4 weeks, then raises the dose in 2.5 mg steps at least 4 weeks apart [1]. Maintenance doses are 5, 10 or 15 mg.
The label gives tirzepatide a half-life of about 5 days. It also notes that most nausea, vomiting and diarrhea in the weight trials came during dose escalation and decreased over time.
Appetite: the first weeks
A 6-week phase 1 trial measured this directly in 114 adults without diabetes with a BMI of 27 to 50 [2]. They were randomized to tirzepatide, placebo or open-label liraglutide.
At week 3, energy intake at a lunch where people could eat as much as they liked was 524.6 kcal lower on tirzepatide than on placebo (95% CI −648.1 to −401.0).
People on tirzepatide also reported less appetite, fewer food cravings, less hunger and less tendency to overeat. This was a short, early-phase study, so it shows the direction and timing rather than long-term size.
Weight: the trial timeline
SURMOUNT-1 enrolled 2,539 adults without diabetes who had a BMI of 30 or more, or 27 or more with a weight-related complication [3]. It ran 72 weeks, including a 20-week dose-escalation period.
Participants reached their target dose at week 4 for 5 mg, week 12 for 10 mg and week 20 for 15 mg [4]. So people on the top dose spent the first five months still climbing.
| Weekly dose | Mean weight change | Lost 5% or more |
|---|---|---|
| Tirzepatide 5 mg | −15.0% | 85% |
| Tirzepatide 10 mg | −19.5% | 89% |
| Tirzepatide 15 mg | −20.9% | 91% |
| Placebo | −3.1% | 35% |
The full picture of how much weight people lost, and how it varied, is in how much weight you can lose on tirzepatide.
What if not much has happened by week 12?
A post hoc analysis of SURMOUNT-1 took this question head on [4]. It included 1,545 people on tirzepatide who received at least 75% of their doses and had weights recorded at weeks 0, 12, 24 and 72.
By week 12, 82% had lost at least 5% of their starting weight. The other 18% were labeled late responders, and they were more often men and heavier at baseline.
Of those late responders, 70% reached a 5% loss by week 24 and 90% by week 72. Their mean time to 5% was 24.8 weeks (SD 12.7), and higher doses went with more weight lost.
What happens if you stop
SURMOUNT-4 gave 783 adults open-label tirzepatide at their highest tolerated dose, 10 or 15 mg, for 36 weeks [5]. The 670 who completed that phase had lost a mean 20.9%, and were randomized to continue or switch to placebo for 52 weeks.
Those who continued lost a further 5.5%, while those switched to placebo regained 14.0%. The authors conclude that stopping led to substantial regain, while continuing maintained and added to the loss.
Related reading
Side effects that cluster in the early months are covered in tirzepatide side effects and tirzepatide diarrhea. What the lost weight is made of is in GLP-1 muscle loss.
The same question for semaglutide is answered in how long it takes for semaglutide to work. To compare prescribers, see the compounded tirzepatide rankings.